依达拉奉联合纤溶酶对急性脑梗死患者的效果研究

Effect of Edaravone Combined with Defibrase on Patients with Acute Cerebral Infarction

目的研究分析依达拉奉联合纤溶酶对急性脑梗死患者的效果。方法2016年8月—2019年8月期间共有100例急性脑梗死患者在蚌埠医学院第一附属医院就诊、治疗,根据计算机随机分组法将患者分为研究组、常规组,每组50例急性脑梗死。常规组50例患者入院后给予肠溶阿司匹林口服(100 mg/d)、灯盏细辛注射液静脉滴注(10 ml/d)、瑞舒伐他汀片口服(5 mg/d)等常规治疗,研究组50例在常规组基础上应用纤溶酶、依达拉奉静脉滴注治疗,在两组治疗14 d后采用统计学方案对比两组治疗结局。结果研究组治疗有效率98%明显大于常规组的80%(P<0.05)。两组治疗前的NIHSS评分比较,差异无统计学意义(P>0.05);研究组治疗7 d、治疗14 d后的NIHSS评分均低于常规组(P<0.05)。研究组治疗期间的不良反应(面色潮红、血肌酐升高、血管炎性反应)发生率8%与常规组10%比较,差异无统计学意义(P>0.05)。结论依达拉奉联合纤溶酶治疗急性脑梗死患者,疗效显著,不良反应少,用药安全性高,值得推广。

Objective To study the effect of Edaravone combined with defibrase on patients with acute cerebral infarction.Methods A total of 100 patients with acute cerebral infarction from August,2016 to August,2019 were treated and treated in the hospital.According to the computer random grouping method,the patients were divided into study group and routine group,with 50 cases of acute cerebral infarction in each group.50 patients in the routine group were treated with enteric aspirin orally(100 mg/d),Danshen injection intravenous drip(10 ml/d)and resuvastatin tablets(10 mg/d)after admission.50 patients in the study group were treated with fibrinolytic enzyme and Edaravonejing on the basis of routine group after 14 d of treatment,and the two groups were treated with statistical protocol.The outcome of treatment was compared.Results The effective rate of treatment in the study group was 98%significantly higher than that in the routine group(P<0.05).There was no difference in NIHSS scores between the two groups before treatment(P>0.05),and the NIHSS scores of the study group after 7 days of treatment and 14 days of treatment were lower than those of the routine group(P<0.05).Incidence of adverse reactions(flushed complexion,elevated serum creatinine and vasculitis)in the study group was 8%compared with 10%in the routine group(P>0.05).Conclusion Edaravone combined with fibrinolysis Enzyme treatment of patients with acute cerebral infarction,the curative effect is remarkable,the adverse reaction is less,and the medication safety is high.So it is worth popularizing.